IONS Ionis Pharmaceuticals

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis. The company was named Isis Pharmaceuticals until December 2015.

Company profile

Brett Monia
Fiscal year end
Former names
IRS number

IONS stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


24 Feb 21
21 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 397.66M 397.66M 397.66M 397.66M 397.66M 397.66M
Cash burn (monthly) 78.47M 23.8M 7.55M 14.34M (positive/no burn) (positive/no burn)
Cash used (since last report) 290.55M 88.14M 27.97M 53.1M n/a n/a
Cash remaining 107.11M 309.53M 369.69M 344.56M n/a n/a
Runway (months of cash) 1.4 13.0 48.9 24.0 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Apr 21 Cadoret-Manier Onaiza Common Stock Payment of exercise Dispose F No No 41.03 1,960 80.42K 4,199
15 Apr 21 Cadoret-Manier Onaiza Common Stock Option exercise Aquire M No No 0 5,667 0 6,159
15 Apr 21 Cadoret-Manier Onaiza RSU Common Stock Option exercise Dispose M No No 0 5,667 0 17,000
1 Mar 21 Brett P Monia Common Stock Sell Dispose S No Yes 54.275 236 12.81K 50,114
26 Feb 21 Brett P Monia Common Stock Other Aquire J No No 44.54 247 11K 50,350
26 Feb 21 C Frank Bennett Common Stock Other Aquire J No No 44.54 112 4.99K 42,620
26 Feb 21 Cadoret-Manier Onaiza Common Stock Other Aquire J No No 44.54 492 21.91K 492
26 Feb 21 Richard S Geary Common Stock Other Aquire J No No 44.54 414 18.44K 41,920

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

  • Our business could be materially adversely affected by the effects of health epidemics. To date, we believe the impacts of the recent COVID-19 pandemic on our business are limited and manageable.
  • We have limited experience as a company in commercializing medicines, and we may have to invest significant resources to develop these capabilities. If we are unable to establish effective marketing, sales and distribution capabilities or enter into agreements with third parties to market, sell and distribute our medicines, we may not be able to generate revenue from our medicines.
  • If the market does not accept our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, we are not likely to generate substantial revenues or become consistently profitable.
  • If we or our partners fail to compete effectively, our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, will not contribute significant revenues.
  • Certain of our medicines may compete with our other medicines, which could reduce our expected revenues.
  • Our medicines could be subject to regulatory limitations following approval.
  • We depend on our collaboration with Biogen for the development and commercialization of SPINRAZA.
  • If we cannot optimize and maintain effective marketing and sales capabilities or enter into agreements with third parties to market and sell TEGSEDI and WAYLIVRA, we may not generate significant product revenue from TEGSEDI or WAYLIVRA.
  • Our operations are subject to additional healthcare laws.
  • If government or other third-party payers fail to provide adequate coverage and payment rates for our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, our revenue will be limited.
  • If we cannot manufacture our medicines or contract with a third party to manufacture our medicines at costs that allow us to charge competitive prices to buyers, we cannot market our products profitably.
  • If we or our partners fail to obtain regulatory approval for our medicines and additional approvals for SPINRAZA, TEGSEDI and WAYLIVRA, we or our partners cannot sell them in the applicable markets.
  • If the results of clinical testing indicate that any of our medicines are not suitable for commercial use, we may need to abandon one or more of our drug development programs.
  • Even if our medicines are successful in preclinical and human clinical studies, the medicines may not be successful in late-stage clinical studies.
  • We depend on third parties to conduct our clinical studies for our medicines and any failure of those parties to fulfill their obligations could adversely affect our development and commercialization plans.
  • Since corporate partnering is a significant part of our strategy to fund the advancement and commercialization of our development programs, if any of our collaborative partners fail to fund our collaborative programs, or if we cannot obtain additional partners, we may have to delay or stop progress on our drug development programs.
  • Even with funding from corporate partners, if our partners do not effectively perform their obligations under our agreements with them, it would delay or stop the progress of our drug development and commercial programs.
  • If we do not progress in our programs as anticipated, the price of our securities could decrease.
  • We have incurred losses, and our business will suffer if we fail to consistently achieve profitability in the future.
  • If we fail to obtain timely funding, we may need to curtail or abandon some of our programs.
  • If we cannot protect our patent rights or our other proprietary rights, others may compete more effectively against us.
  • Intellectual property litigation could be expensive and prevent us from pursuing our programs.
  • If we fail to successfully integrate Akcea’s business and operations, it may adversely affect our future results.
  • If our management transition is not successful our business could suffer.
  • The loss of key personnel, or the inability to attract and retain highly skilled personnel, could make it more difficult to run our business and reduce our likelihood of success.
  • Our ability to use our net operating loss carryovers and certain other tax attributes may be limited.
  • Our future taxable income could be impacted by changes in tax laws, regulations and treaties.
  • We could be subject to additional tax liabilities.
  • If the price of our securities continues to be highly volatile, this could make it harder for you to liquidate your investment and could increase your risk of suffering a loss.
  • Provisions in our certificate of incorporation, convertible notes documents, call spread hedge transaction documents and Delaware law may prevent stockholders from receiving a premium for their shares.
  • Future sales of our common stock in the public market could adversely affect the trading price of our securities.
  • We are exposed to potential product liability claims, and insurance against these claims may not be available to us at a reasonable rate in the future or at all.
  • We are dependent on information technology systems, infrastructure and data, which exposes us to data security risks.
  • Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
  • If a natural or man-made disaster strikes our research, development or manufacturing facilities or otherwise affects our business, it could delay our progress developing and commercializing our medicines.
  • Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance.
  • Negative conditions in the global credit markets and financial services and other industries may adversely affect our business.
  • The impact on us of the vote by the United Kingdom to leave the European Union cannot be predicted.
Content analysis
H.S. freshman V good
New words: abeparvovec, abroad, abundance, accomplished, ACE, airflow, airway, allege, analogue, angiotensin, antihyperlipidemic, Aon, aro, artificial, ataxin, autophagy, Avalanche, belief, benchmark, beneficiary, Biden, BioPharma, biopsy, biosimilar, Biovail, Biovitrum, breakthrough, bribery, Bridgebio, Britain, brought, BV, calendar, capping, career, carryback, certainty, choice, clarity, closer, Commonwealth, constitutionality, contractor, convertase, convict, convicted, cooperation, COPD, counterfeit, cultivate, culture, CVDRR, de, Delinquent, dental, diminished, diplomatic, disaccharide, disgorgement, dismissed, dispersed, diverge, DSCA, emergency, empower, empowered, enjoyed, EPS, ESRD, eugene, exit, expert, feel, Flamingo, formulary, fraudulent, freestanding, furlough, gender, Governor, Great, Hammersmith, harmonizing, heard, Hewitt, holiday, hydration, illegal, illegitimate, immigration, impeded, imposition, imprisonment, incompatibility, induce, Infant, inflation, instability, interferon, internationally, John, knowingly, labor, learning, left, library, lifestyle, lomitapide, marketplace, mastinib, meglumine, Microsomal, monotherapy, motivating, MSA, MTP, Nacional, NaN, nebulizer, obstructed, obstructive, onasemnogene, outbreak, Overview, pandemic, panel, PDMA, pegylated, pelacarsen, penalty, perspective, pertinent, phenotyping, phishing, pioneer, pioneering, prejudice, Prejudicial, principle, programunder, proportion, proprotein, punishable, quantitation, race, Radford, referenced, referral, regime, reinstated, rejoin, rejoining, remotely, remuneration, renaming, restructured, retention, revalued, rewarded, rewarding, rigid, SBP, schneider, session, sHTG, sick, sleep, Sobi, SRLY, staffing, statute, stay, stereotaxic, stipulation, strain, stronger, suboptimal, Surveillance, survey, suspension, Swedish, switched, Synageva, systolic, TG, thousand, tracing, travel, traveling, trehalose, turnover, tying, unallocated, unaware, unexpected, unfavorable, UniQure, unnecessary, unrest, Vacation, vast, visit, volunteer, volunteering, vupanorsen, welfare, willingly, woodsmoke, wrongdoing, younger
Removed: accumulate, adjusted, affecting, affiliate, alongside, AMT, anabolic, Anderson, antitumor, ASO, atherogenic, augment, BROADEN, carcinoma, centrally, comparison, constipation, contractually, count, declining, delivering, depth, dialkyl, dilute, discontinuation, distributable, distributed, diverse, division, eliminated, employ, Endocrinology, epigenetic, equally, essentially, ether, exciting, expanding, extinguished, extinguishment, flat, FPL, fundamentally, half, headache, hepatocellular, Hybridon, imposing, inheriting, instance, intangible, judgmental, leased, leptin, leveraging, LIBOR, lipodystrophy, liquidation, London, lymphoma, MD, metreleptin, misfolded, Monocalcium, necessarily, neurologic, optimal, partnership, PDUFA, pituitary, preferentially, preparing, profound, programmed, progressively, proven, puncture, reclassify, released, reliably, replacement, salt, secondarily, sensation, sensitivity, simplify, solid, spectrum, swap, unmet, unrepatriated, urinary, wealth